Skip to content


  • Oral presentation
  • Open Access

Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma

  • Aizea Morales-Kastresana1,
  • Sanmamed F Miguel1, 2,
  • Inmaculada Rodriguez2,
  • Asis Palazon1,
  • Ivan Martinez-Forero1,
  • Sara Labiano1,
  • Sandra Hervas-Stubbs1,
  • Bruno Sangro2,
  • Carmen Ochoa1,
  • Ana Rouzaut1,
  • Arantza Azpilikueta1,
  • Elixabet Bolaños1,
  • Maria Jure-Kunkel3,
  • Ines Gutgemann4 and
  • Ignacio Melero1
Journal for ImmunoTherapy of Cancer20131(Suppl 1):O7

Published: 7 November 2013


Hepatocellular CarcinomaTumor Bear MouseTumor Lymphocyte InfiltratePrimary Liver CancerAntitumor Immune Response

Several immunostimulatory monoclonal antibodies (ISmAbs) that derepress and unleash antitumor immune responses are showing efficacy in cancer clinical trials. MAbs anti-B7-H1 (PD-L1) block a critical inhibitory pathway for T cells, while antibodies anti-CD137 and OX40 provide intense T cell costimulation. Documenting efficacy of immunotherapies on spontaneous tumors arising in oncogene transgenic mice is considered more predictive than experiments on transplanted tumors. A combination of these ISmAbs has been tested on a transgenic mouse model of spontaneous primary liver cancer in which c-myc drives transformation and the tumor cells express ovalbumin as a surrogate transgenic antigen. The induced tumor lymphocyte infiltrates and immune mechanisms of action were studied. The triple combination of mAbs clearly extended survival of mice bearing hepatocellular carcinomas (HCC) and synergized with adoptive T cell therapy with activated TCR-transgenic T cells that recognize OVA. Mice undergoing therapy showed a clear increase in the tumor tissue infiltration by activated and blastic CD8 T lymphocytes expressing the ISmAb-targeted receptors. The triple combination of ISmAbs did not result in enhanced OVA-specific CTL activity but other antigens in cell lines derived from such HCC were recognized by the elicited tumor infiltrating T lymphocytes. Indeed adoptive transfer of OT-1 cells to tumor bearing mice resulted in their tolerization, unless the triple mAb therapy was instigated. Our results emphasize the role of combinational immunotherapy approaches including ISmAbs to impact on agressive and highly T cell-tolerizing hepatocellular carcinomas.

Authors’ Affiliations

CIMA, Pamplona, Spain
CUN, Pamplona, Spain
Bristol Myers Squibb, Lawrenceville, USA
University of Bonn, Bonn, Germany


© Morales-Kastresana et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.